Weight Watchers integrates with Eli Lilly's LillyDirect platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- Oil rises 1% on US-Iran deal doubts; IEA warns of supply glut
Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'
June 5, 2026 7:38 AM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,344.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Mounjaro TRx/NRx scripts for the week ending 5/29/26 were ~756,700/353,700 (vs. ~796,800/388,900 last week) per IQVIA data. Zepbound TRx/NRx scripts were ~610,800/328,300 (vs. ~659,000/360,200 last week). We see ~7% upside to '26 M+Z ests. We are monitoring the launches of LLY's Mounjaro (injectable GLP-GIP) for type 2 diabetes (T2D), and Zepbound (injectable GLP-GIP) for obesity, and Foundayo (oral GLP) given these are the company's key product cycles. Total GLP-1 TRx (LLY+Novo) grew ~32% yoy (see... More
